<VariationArchive RecordType="classified" VariationID="831385" VariationName="NC_000010.11:g.(?_87925503)_(87965482_?)del" VariationType="Deletion" Accession="VCV000831385" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-10-21" DateCreated="2020-04-15" MostRecentSubmission="2020-04-15">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="820267" VariationID="831385">
      <GeneList>
        <Gene Symbol="PTEN" FullName="phosphatase and tensin homolog" GeneID="5728" HGNC_ID="HGNC:9588" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>10q23.31</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="10" Accession="NC_000010.11" start="87863625" stop="87971930" display_start="87863625" display_stop="87971930" Strand="+" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="10" Accession="NW_013171807.1" start="79449" stop="187719" display_start="79449" display_stop="187719" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="10" Accession="NC_000010.10" start="89623194" stop="89728531" display_start="89623194" display_stop="89728531" Strand="+" />
          </Location>
          <OMIM>601728</OMIM>
          <Haploinsufficiency last_evaluated="2020-06-24" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=PTEN">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-06-24" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=PTEN">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NC_000010.11:g.(?_87925503)_(87965482_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>10q23.31</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="10" Accession="NC_000010.10" innerStart="89685260" innerStop="89725239" display_start="89685260" display_stop="89725239" variantLength="39980" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000010.10" sequenceAccession="NC_000010" sequenceVersion="10" change="g.(?_89685260)_(89725239_?)del" Assembly="GRCh37">
            <Expression>NC_000010.10:g.(?_89685260)_(89725239_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000010.11:g.(?_87925503)_(87965482_?)del AND PTEN hamartoma tumor syndrome" Accession="RCV001031943" Version="1">
        <ClassifiedConditionList TraitSetID="2131">
          <ClassifiedCondition DB="MedGen" ID="C1959582">PTEN hamartoma tumor syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-06-12" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2019-06-12" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2020-04-15" MostRecentSubmission="2020-04-15">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10468583</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">10698513</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">10866658</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">11035045</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12297295</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20223021</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22382802</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24905788</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27477328</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28086757</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="2131" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="10363" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">PTEN hamartoma tumor syndrome</ElementValue>
                <XRef ID="MONDO:0017623" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PTEN-related disorders</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">PTEN Hamartomatous Tumour Syndrome</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PHTS</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">The PTEN hamartoma tumor syndrome (PHTS) includes Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), and PTEN-related Proteus-like syndrome. CS is a multiple hamartoma syndrome with a high risk for benign and malignant tumors of the thyroid, breast, kidney, and endometrium. Affected individuals usually have macrocephaly, trichilemmomas, and papillomatous papules, and present by the late 20s. The lifetime risk of developing breast cancer is 85%, with an average age of diagnosis between 38 and 46 years. The lifetime risk for thyroid cancer (usually follicular, rarely papillary, but never medullary thyroid cancer) is approximately 35%. The lifetime risk for renal cell cancer (predominantly of papillary histology) is 34%. The risk for endometrial cancer may approach 28%. BRRS is a congenital disorder characterized by macrocephaly, intestinal hamartomatous polyposis, lipomas, and pigmented macules of the glans penis. PS is a complex, highly variable disorder involving congenital malformations and hamartomatous overgrowth of multiple tissues, as well as connective tissue nevi, epidermal nevi, and hyperostoses. Proteus-like syndrome is undefined but refers to individuals with significant clinical features of PS who do not meet the diagnostic criteria for PS.</Attribute>
                <XRef ID="NBK1488" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000552184" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552302" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558905" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551654" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000326160" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552440" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000595970" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12800" />
                <XRef ID="12800" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301661</ID>
                <ID Source="BookShelf">NBK1488</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23519317</ID>
              </Citation>
              <Citation Type="general" Abbrev="NCCN, 2014">
                <ID Source="PubMed">25190698</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACG, 2015">
                <ID Source="PubMed">25645574</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Skin Cancer">
                <ID Source="PubMed">26389333</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Genetics of Colorectal Cancer">
                <ID Source="PubMed">26389505</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <XRef ID="306498" DB="Orphanet" />
              <XRef ID="C1959582" DB="MedGen" />
              <XRef ID="D006223" DB="MeSH" />
              <XRef ID="MONDO:0017623" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2356505" SubmissionDate="2020-02-06" DateLastUpdated="2020-04-15" DateCreated="2020-04-15">
        <ClinVarSubmissionID localKey="6809945|MedGen:C1959582" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001195250" DateUpdated="2020-04-15" DateCreated="2020-04-15" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-06-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">20223021</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22382802</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27477328</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24905788</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10866658</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11035045</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10468583</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10698513</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12297295</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28086757</ID>
          </Citation>
          <Comment>This variant is a gross deletion of the genomic region encompassing exons 3-9. The 5' boundary is likely confined to intron 2. The 3' end of this event is unknown as it extends through the termination codon beyond the assayed region for this gene and may encompass additional genes. While this deletion is not anticipated to result in nonsense mediated decay, it is expected to create a truncated protein product or disrupt mRNA translation. A similar deletion has been observed in an individual clinical features of Cowden syndrome (PMID: 22382802). Experimental studies have shown that disruption of the C-terminal portion of the C2 domain, as well as the entire C-tail domain and PDZ binding domain, affects the stability and function of the PTEN protein (PMID: 10468583, 10698513, 24905788). This variant also removes several critical phosphorylation sites within the C-tail, which are important for regulating PTEN protein stability and function (PMID: 12297295, 10866658, 11035045, 10468583). Variants that disrupt the C-terminus in PTEN have been observed in affected individuals (PMID: 20223021, 27477328, 28086757, Invitae). This suggests that this region is clinically significant, and that other variants that disrupt it are likely to be causative of disease. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PTEN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000010.10:g.(?_89685260)_(89725239_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">PTEN hamartoma tumor syndrome</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C1959582" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB6933794</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2356505" TraitType="Disease" MappingType="Name" MappingValue="PTEN hamartoma tumor syndrome" MappingRef="Preferred">
        <MedGen CUI="C1959582" Name="PTEN hamartoma tumor syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

